|
시장보고서
상품코드
1562380
아시아태평양의 사코페니아 치료 시장 전망(-2030년) : 지역별 분석 - 치료 유형별, 유통 채널별, 지역별 분석Asia Pacific Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel |
||||||
아시아태평양의 사코페니아 치료 시장은 2022년 6억 9,685만 달러로 평가되었습니다. 2030년에는 11억 6,404만 달러에 달할 것으로 예상되며, 2022-2030년간 연평균 6.6%의 성장률을 나타낼 것으로 예상됩니다.
임상시험 단계의 제품이 아시아태평양의 사코페니아 치료제 시장을 주도하고 있습니다.
근감소증 치료 시장에 진출한 여러 대기업들이 근감소증 치료제 개발에 점점 더 많은 노력을 기울이고 있습니다. 현재 새로운 사코페니아 치료제가 개발되어 임상시험이 진행되고 있습니다.
따라서 임상 개발 단계에 있는 다양한 약품 파이프라인의 출현은 사코페니아 치료제 시장의 성장에 큰 기회가 될 것입니다.
아시아태평양의 사코페니아 치료제 시장 개요
아시아태평양의 사코페니아 치료 시장은 중국, 인도, 일본, 한국, 호주, 기타 아시아태평양으로 구분됩니다. 아시아태평양은 예측 기간 동안 세계 시장에서 가장 빠른 CAGR을 나타낼 것으로 예상됩니다. 아시아는 세계에서 가장 인구가 많고 빠르게 고령화되는 대륙이며, 아시아 여러 국가에서 근육 감소증과 관련된 문제가 만연하고 있습니다. 아시아인의 라이프스타일은 서양인과 크게 다르며 식습관도 다릅니다. 아시아에서는 남성(9.6-22.1%)이 여성(7.7-21.8%)보다 남성(9.6-22.1%)에게서 더 많이 발생하며, 아시아 근감소증 워킹그룹(Asian Working Group for Sarcopenia, AWGS)은 아시아에서 근감소증 연구를 촉진하는 것을 목표로 하고 있습니다.
아시아태평양의 사코페니아 치료제 시장 매출 및 2030년까지 예측(금액)
아시아태평양의 사코페니아 치료제 시장 세분화
아시아태평양 근육 감소증 치료 시장은 치료 유형, 유통 채널 및 국가별로 분류됩니다.
치료 유형별로는 비타민D 및 칼슘 보충제, 단백질 보충제, 비타민 B12 보충제, 기타로 구분되며, 2022년 아시아태평양의 사코페니아 치료 시장은 비타민D 및 칼슘 보충제 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 칼슘 보충제 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
유통 채널에 따라 아시아태평양의 근육 감소증 치료 시장은 약국, 소매 채널, 온라인 채널 및 기타로 구분되며, 2022년 아시아태평양의 근육 감소증 치료 시장 점유율은 약국 부문이 가장 큰 것으로 나타났습니다.
국가별로는 아시아태평양의 근육 감소증 치료 시장은 중국, 인도, 일본, 호주, 한국, 기타 아시아태평양으로 구분되며, 2022년 아시아태평양의 근육 감소증 치료 시장 점유율은 중국이 독점할 것으로 예상됩니다.
Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, GSK Plc는 아시아태평양의 사코페니아 치료제 시장에서 사업을 운영하는 주요 기업 중 일부입니다.
목차
제1장 서론
제2장 주요 요약
- 주요 인사이트
제3장 조사 방법
- 조사 범위
- 2차 조사
- 1차 조사
제4장 아시아태평양의 사코페니아 치료 시장 - 주요 산업 역학
- 아시아태평양의 사코페니아 치료 시장 : 주요 산업 역학
- 시장 성장 촉진요인
- 주요 시장 성장 억제요인
- 주요 시장 기회
- 향후 동향
- 성장 촉진요인과 억제요인의 영향
제5장 사코페니아 치료 시장 : 아시아태평양 시장 분석
- 아시아태평양의 사코페니아 치료 시장 매출(2020-2030년)
- 아시아태평양의 사코페니아 치료 시장 예측과 분석
제6장 아시아태평양의 사코페니아 치료 시장 분석 - 치료 유형별
- 비타민 D 및 칼슘 보충제
- 단백질 보충제
- 비타민 B12 보충제
- 기타
제7장 아시아태평양의 사코페니아 치료 시장 분석 - 유통 채널별
- 약국
- 소매 채널
- 온라인 채널
- 기타
제8장 아시아태평양의 사코페니아 치료 시장 : 국가별 분석
- 아시아태평양
- 중국
- 인도
- 일본
- 한국
- 호주
- 기타 아시아태평양
제9장 사코페니아 치료 시장 - 업계 상황
- 서론
- 사코페니아 치료 시장 성장 전략
- 무기적 성장 전략
- 유기적 성장 전략
제10장 기업 개요
- Abbott Laboratories
- Bayer AG
- Metagenics LLC
- Nestle Health Science SA
- Novartis AG
- Pfizer Inc
- Sanofi SA
- Amway Corp
- GSK Plc
제11장 부록
LSH 24.10.25The Asia Pacific sarcopenia treatment market was valued at US$ 696.85 million in 2022 and is expected to reach US$ 1,164.04 million by 2030; it is estimated to register a CAGR of 6.6% from 2022 to 2030.
Products in Clinical Trial Phases Drive Asia Pacific Sarcopenia Treatment Market
A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:
- Table 1. Sarcopenia Drug Under Clinical Development
Company Name Interventions Conditions Clinical Trial Stage
Abbott Nutrition Medical Food with AN777
Oral Nutritional Formula Malnutrition
Sarcopenia PHASE3
Nutricia Research Dietary Supplement: Bolus ONS A
Dietary Supplement: Bolus ONS B
Dietary Supplement: Bolus ONS C
Dietary Supplement: Bolus ONS D Sarcopenia PHASE1
Novartis Pharmaceuticals Drug: Bimagrumab Sarcopenia PHASE2
McMaster University Behavioural: Step Reduction Sarcopenia PHASE1
Metabolic Technologies Inc. Dietary Supplement: Placebo
Drug: HMB Plus Vitamin D
Behavioural: Non-Exercise
Behavioural: Exercise Sarcopenia PHASE1
Merck Sharp & Dohme LLC Drug: Comparator MK-077
Drug: Comparator Placebo Sarcopenia PHASE2
Immunotec Inc. Dietary Supplement: Immunocal
Dietary Supplement: Casein Aging and Sarcopenia PHASE2
Lijun Yang Combination Product: 3-Month Intensive Intervention Sarcopenia PHASE4
Regeneron Pharmaceuticals Drug: REGN1033 (SAR391786)
Drug: Placebo Sarcopenia PHASE2
Source: Company Websites and The Insight Partners Analysis
Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.
Asia Pacific Sarcopenia Treatment Market Overview
The Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. Asia is the world's most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians led extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6-22.1%) than females (prevalence 7.7-21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research in Asia.
Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Sarcopenia Treatment Market Segmentation
The Asia Pacific sarcopenia treatment market is categorized into treatment type, distribution channel, and country.
Based on treatment type, the Asia Pacific sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Asia Pacific sarcopenia treatment market share in 2022.
In terms of distribution channel, the Asia Pacific sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Asia Pacific sarcopenia treatment market share in 2022.
By country, the Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific sarcopenia treatment market share in 2022.
Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Asia Pacific sarcopenia treatment market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics
- 4.1 Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics
- 4.2 Market Drivers
- 4.2.1 Upsurge in Geriatric Population
- 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
- 4.3 Key Market Restraints:
- 4.3.1 Unavailability of Direct Interventions
- 4.4 Key Market Opportunities:
- 4.4.1 Products in Clinical Trial Phases
- 4.5 Future Trends:
- 4.5.1 Rising Awareness About Sarcopenia
- 4.6 Impact of Drivers and Restraints:
5. Sarcopenia Treatment Market - Asia Pacific Market Analysis
- 5.1 Asia Pacific Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
- 5.2 Asia Pacific Sarcopenia Treatment Market Forecast and Analysis
6. Asia Pacific Sarcopenia Treatment Market Analysis - By Treatment Type
- 6.1 Vitamin D and Calcium Supplement
- 6.1.1 Overview
- 6.1.2 Vitamin D and Calcium Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
- 6.2 Protein Supplement
- 6.2.1 Overview
- 6.2.2 Protein Supplement : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
- 6.3 Vitamin B12 Supplement
- 6.3.1 Overview
- 6.3.2 Vitamin B12 Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
- 6.4 Others
- 6.4.1 Overview
- 6.4.2 Others : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Sarcopenia Treatment Market Analysis - By Distribution Channel
- 7.1 Pharmacies
- 7.1.1 Overview
- 7.1.2 Pharmacies : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
- 7.2 Retail Channels
- 7.2.1 Overview
- 7.2.2 Retail Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
- 7.3 Online Channels
- 7.3.1 Overview
- 7.3.2 Online Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
- 7.4 Others
- 7.4.1 Overview
- 7.4.2 Others : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Sarcopenia Treatment Market - Country Analysis
- 8.1 Asia Pacific
- 8.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
- 8.1.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
- 8.1.1.2 China Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
- 8.1.1.2.1 China Sarcopenia Treatment Market Breakdown by Treatment Type
- 8.1.1.2.2 China Sarcopenia Treatment Market Breakdown by Distribution Channel
- 8.1.1.3 India Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
- 8.1.1.3.1 India Sarcopenia Treatment Market Breakdown by Treatment Type
- 8.1.1.3.2 India Sarcopenia Treatment Market Breakdown by Distribution Channel
- 8.1.1.4 Japan Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
- 8.1.1.4.1 Japan Sarcopenia Treatment Market Breakdown by Treatment Type
- 8.1.1.4.2 Japan Sarcopenia Treatment Market Breakdown by Distribution Channel
- 8.1.1.5 South Korea Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
- 8.1.1.5.1 South Korea Sarcopenia Treatment Market Breakdown by Treatment Type
- 8.1.1.5.2 South Korea Sarcopenia Treatment Market Breakdown by Distribution Channel
- 8.1.1.6 Australia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
- 8.1.1.6.1 Australia Sarcopenia Treatment Market Breakdown by Treatment Type
- 8.1.1.6.2 Australia Sarcopenia Treatment Market Breakdown by Distribution Channel
- 8.1.1.7 Rest of Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
- 8.1.1.7.1 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Treatment Type
- 8.1.1.7.2 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Distribution Channel
- 8.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
9. Sarcopenia Treatment Market-Industry Landscape
- 9.1 Overview
- 9.2 Growth Strategies in the Sarcopenia Treatment Market
- 9.3 Inorganic Growth Strategies
- 9.3.1 Overview
- 9.4 Organic Growth Strategies
- 9.4.1 Overview
10. Company Profiles
- 10.1 Abbott Laboratories
- 10.1.1 Key Facts
- 10.1.2 Business Description
- 10.1.3 Products and Services
- 10.1.4 Financial Overview
- 10.1.5 SWOT Analysis
- 10.1.6 Key Developments
- 10.2 Bayer AG
- 10.2.1 Key Facts
- 10.2.2 Business Description
- 10.2.3 Products and Services
- 10.2.4 Financial Overview
- 10.2.5 SWOT Analysis
- 10.2.6 Key Developments
- 10.3 Metagenics LLC
- 10.3.1 Key Facts
- 10.3.2 Business Description
- 10.3.3 Products and Services
- 10.3.4 Financial Overview
- 10.3.5 SWOT Analysis
- 10.3.6 Key Developments
- 10.4 Nestle Health Science SA
- 10.4.1 Key Facts
- 10.4.2 Business Description
- 10.4.3 Products and Services
- 10.4.4 Financial Overview
- 10.4.5 SWOT Analysis
- 10.4.6 Key Developments
- 10.5 Novartis AG
- 10.5.1 Key Facts
- 10.5.2 Business Description
- 10.5.3 Products and Services
- 10.5.4 Financial Overview
- 10.5.5 SWOT Analysis
- 10.5.6 Key Developments
- 10.6 Pfizer Inc
- 10.6.1 Key Facts
- 10.6.2 Business Description
- 10.6.3 Products and Services
- 10.6.4 Financial Overview
- 10.6.5 SWOT Analysis
- 10.6.6 Key Developments
- 10.7 Sanofi SA
- 10.7.1 Key Facts
- 10.7.2 Business Description
- 10.7.3 Products and Services
- 10.7.4 Financial Overview
- 10.7.5 SWOT Analysis
- 10.7.6 Key Developments
- 10.8 Amway Corp
- 10.8.1 Key Facts
- 10.8.2 Business Description
- 10.8.3 Products and Services
- 10.8.4 Financial Overview
- 10.8.5 SWOT Analysis
- 10.8.6 Key Developments
- 10.9 GSK Plc
- 10.9.1 Key Facts
- 10.9.2 Business Description
- 10.9.3 Products and Services
- 10.9.4 Financial Overview
- 10.9.5 SWOT Analysis
- 10.9.6 Key Developments
11. Appendix
- 11.1 About The Insight Partners
- 11.2 Glossary of Terms
